



Date: 3rd February, 2025

To,
The Manager,
Department of Corporate Services,
BSE Limited
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001
Scrip Code: 533573

To,
The Manager,
Listing Department,
National Stock Exchange of India Ltd.
'Exchange Plaza', Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
NSE Symbol: APLLTD

Dear Sir/Madam,

Sub: Press Release on the Unaudited Financial Results for the quarter and nine months period ended 31st December, 2024.

With reference to the captioned subject, please find enclosed herewith Press Release on the Unaudited Financial Results for the quarter and nine months period ended 31st December, 2024.

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,
For Alembic Pharmaceuticals Limited

Manisha Saraf
Company Secretary

Encl.: A/a.

ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE: ALEMBIC ROAD, VADODARA - 390 003. • TEL: (0265) 2280550, 2280880 • FAX: (0265) 2281229
Website : www.alembicpharmaceuticals.com • E-mail : alembic@alembic.co.in • CIN : L24230GJ2010PLC061123



Press Release

Net Revenue up 4%

Profit Before Tax at Rs. 179 Crores

Mumbai, February 3rd, 2025

Alembic Pharmaceuticals Limited reported its consolidated financial results for the third quarter ended 31st December, 2024.

Financial Highlights

- Net Sales increased by 4% to Rs.1693 Crores.
- EBITDA up 1% to Rs. 271 Crores
- EBITDA Margin at 16% of Sales
- Net Profit at Rs.138 Crores

Mr. Shaunak Amin, MD, Alembic Pharmaceuticals Limited said. "In the current quarter, we faced market headwinds in the acute segment. However, other key therapies in our specialty business continued to outpace the market growth. To strengthen field force efficiency, we have enhanced Automation and AI, to upscale execution. This Transition has partly impacted quarter growth. We are confident to show a robust growth trajectory going forward. The US Business posted significant volume growth and the Ex-US markets continued to expand steadily. API Business is still under significant pricing pressure."

Operational Highlights

India Branded Business

- India Branded Business grew 3% to Rs. 614 crores for the quarter.
- Animal Health business grew 22% for the quarter with basket of strong brands driving outperformance.
- Specialty therapies recorded growth of 6%.
- 3 launches during the quarter. New launches continue to do well along with promising future launches across key segments.

International Business

- US Generics grew 10% to Rs. 521 Crores for the quarter.
- 2 Launches in the US market during the quarter.
- Ex-US International Generics grew 10% to Rs. 299 Crores for the quarter.
- 7 ANDA approvals received during the quarter, 219 Cumulative ANDA approvals.

ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE: ALEMBIC ROAD, VADODARA - 390 003. • TEL: (0265) 2280550, 2280880 • FAX: (0265) 2281229
Website : www.alembicpharmaceuticals.com • E-mail : alembic@alembic.co.in • CIN : L24230GJ2010PLC061123

API Business

- API business at Rs. 259 Crores for the quarter.

The summary of Total Revenue is as under:

(Rs in Crores)

Particulars	Q3 FY25	Q3 FY24	% Change	9M FY25	9M FY24	% Change
Formulation						
India	614	596	3%	1795	1697	6%
USA	521	474	10%	1449	1308	11%
Ex- US	299	272	10%	868	790	10%
API	259	289	(10%)	791	916	(14%)
Total	1693	1631	4%	4902	4712	4%

About Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the US FDA. Alembic is one of the leaders in branded generics in India. Alembic's brands, marketed through a field force of over 5200 are well recognized by doctors and patients.

Information about the company can be found at www.alembicpharmaceuticals.com;
(reuters:ALEM.NS) (bloomberg:ALPM) (nse:APLLTD) (bse:533573)

For more information, contact:

Ajay Kumar Desai

Phone: +91 022- 66953681

Email: ajay.desai@alembic.co.in

ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE: ALEMBIC ROAD, VADODARA - 390 003. • TEL: (0265) 2280550, 2280880 • FAX: (0265) 2281229
Website : www.alembicpharmaceuticals.com • E-mail : alembic@alembic.co.in • CIN : L24230GJ2010PLC061123